Literature DB >> 16357022

RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients.

L Mercatali1, V Valenti, D Calistri, S Calpona, G Rosti, S Folli, M Gaudio, G L Frassineti, D Amadori, E Flamini.   

Abstract

BACKGROUND: The aim of the present study was to evaluate the accuracy of two markers, maspin and mammaglobin B, singly or in combination, to detect breast cancer. To define better the potential and limits of the two markers for diagnostic purposes, blood positivity was analyzed in relation to clinical, pathological and biological tumor characteristics. PATIENTS AND METHODS: The markers were determined in peripheral blood (PB) samples from 27 healthy donors and 140 previously untreated patients using nested reverse transcriptase polymerase chain reaction (RT-PCR).
RESULTS: Positivity for maspin in blood samples was observed in 24% of patients with an 89% specificity. For mammaglobin B, positivity was observed in 7% of patients and never in healthy donors. The presence of maspin was correlated with cell proliferation of the primary tumor (P = 0.015), whereas mammaglobin B positivity correlated with pathological stage (P = 0.013). The presence of either marker was significantly related to nodal status.
CONCLUSIONS: Our results indicate that the two markers in association could represent a potentially useful non-invasive tool to detect breast cancer. The validation of these markers as indicators of high risk of relapse is ongoing in a series of patients with an adequate follow-up.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16357022     DOI: 10.1093/annonc/mdj109

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  7 in total

Review 1.  Maspin: the new frontier.

Authors:  Zhila Khalkhali-Ellis
Journal:  Clin Cancer Res       Date:  2006-12-15       Impact factor: 12.531

2.  A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.

Authors:  Elisabeth I Heath; David W Hillman; Ulka Vaishampayan; Shijie Sheng; Fazlul Sarkar; Felicity Harper; Melvin Gaskins; Henry C Pitot; Winston Tan; S Percy Ivy; Roberto Pili; Michael A Carducci; Charles Erlichman; Glenn Liu
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

3.  Effects of 5-Aza-CdR on cell proliferation of breast cancer cell line MDA-MB-435S and expression of maspin gene.

Authors:  Bo Zhang; Tao Huang; Ke Liu; Jianying Chen; Guobin Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-10

4.  Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy.

Authors:  S Bellone; R Tassi; M Betti; D English; E Cocco; S Gasparrini; I Bortolomai; J D Black; P Todeschini; C Romani; A Ravaggi; E Bignotti; E Bandiera; L Zanotti; S Pecorelli; L Ardighieri; M Falchetti; C Donzelli; E R Siegel; M Azodi; D-A Silasi; E Ratner; P E Schwartz; T J Rutherford; A D Santin
Journal:  Br J Cancer       Date:  2013-06-27       Impact factor: 7.640

Review 5.  Human mammaglobin in breast cancer: a brief review of its clinical utility.

Authors:  Fawwaz Shakir Al Joudi
Journal:  Indian J Med Res       Date:  2014-05       Impact factor: 2.375

6.  Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: interim results of a prospective cohort study.

Authors:  Kaidi Mikhitarian; Renee Hebert Martin; Megan Baker Ruppel; William E Gillanders; Rana Hoda; Del H Schutte; Kathi Callahan; Michael Mitas; David J Cole
Journal:  BMC Cancer       Date:  2008-02-20       Impact factor: 4.430

7.  The expression of CK-19 gene in circulating tumor cells of blood samples of metastatic breast cancer women.

Authors:  Setareh Soltani; Fariborz Mokarian; Mojtaba Panjehpour
Journal:  Res Pharm Sci       Date:  2015 Nov-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.